Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon
Nkene, Yvette Mawamba
AffiliationCentral Hospital, Yaoundé, Cameroon; Institut de recherche pour le developpement, University of Montpellier, Montpellier, France; Laboratoire de Toxicologie et de Dosage de Medicaments, Centre Hospitalier Universitaire Bichat Claude Bernard, Paris, France; Medecins Sans Frontieres, Geneva, Switzerland; Projet PRESICA (Prevention du Sida au Cameroun), Military Hospital, Yaounde, Cameroon
MetadataShow full item record
AbstractOBJECTIVES: To compare adherence to antiretroviral therapy using drug level monitoring and self-report and to explore the relation between these 2 methods and viral load measurements. METHODS: Sixty patients received a fixed-dose combination of nevirapine, stavudine, and lamivudine in a clinical study in Cameroon. Adherence was assessed every 6 months until month 36 by nevirapine minimal plasma concentration and self-report. Plasma HIV-1 viral load was determined at the same time. Analyses included 159 complete observations. RESULTS: The proportion of patients labeled as "adherent" was significantly lower using nevirapine monitoring (88.7%, 95% confidence interval [CI]: 82.7 to 93.2) than self-report (97.5%, CI: 93.7 to 99.3; P = 0.002). Virologic failure was associated with the nevirapine concentration (adjusted odds ratio [aOR] = 4.43; P = 0.018) but not with the self-reported adherence (aOR = 0.84; P = 0.9). As compared with the virologic outcome, the sensitivity of nevirapine level monitoring for predicting inadequate adherence was 20.5%, the specificity was 91.7%, the positive predictive value was 44.4%, and the negative predictive value was 78.0%. For self-report, the respective values were 2.6%, 97.5%, 25.0%, and 75.5%. CONCLUSIONS: Drug level monitoring provided a more reliable estimate of adherence than self-report. This method could be used in research settings. Operational research is required to define how to improve the accuracy of the self-report method because it is the most feasible method in clinical practice.
- Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study.
- Authors: Parienti JJ, Massari V, Reliquet V, Chaillot F, Le Moal G, Arvieux C, Vabret A, Verdon R, POSOVIR Study Group.
- Issue date: 2007 Oct 18
- Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand.
- Authors: Tsuchiya N, Pathipvanich P, Yasuda T, Mukoyama Y, Rojanawiwat A, Matsubayashi T, Saeng-aroon S, Auwanit W, Matsuyama A, Sawanpanyalert P, Ariyoshi K
- Issue date: 2009 Jan
- Predictors of short-term success of antiretroviral therapy in HIV infection.
- Authors: Oette M, Kroidl A, Göbels K, Stabbert A, Menge M, Sagir A, Kuschak D, O'hanley T, Bode JG, Häussinger D
- Issue date: 2006 Jul
- Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial.
- Authors: Weber R, Christen L, Christen S, Tschopp S, Znoj H, Schneider C, Schmitt J, Opravil M, Günthard HF, Ledergerber B, Swiss HIV Cohort Study.
- Issue date: 2004 Feb
- Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting.
- Authors: Fairley CK, Permana A, Read TR
- Issue date: 2005 Sep